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Botryoid rhabdomyosarcoma of the biliary tract in children: a unique case report
 
Rhabdomyosarcoma (RMS) is the most common tumour of the biliary tree in childhood. In children, it is a
rare lesion, accounting for about 1% of all RMS. Hepatobiliary botryoid RMS is a disease affecting young
children at a median age of about 3 years. In literature, the radiological findings of hepatobiliary RMS have
been described in small series and some case reports. In this case report, we present a rare case of RMS of the
extrahepatic biliary tree initially diagnosed as a choledochal cyst.
 
Keywords:
 
 rhabdomyosarcoma, biliary tree, botryoid.
 
Correspondence address: Nicola Zampieri, Pediatric Surgical Unit, Poli-
clinico ‘G. B. Rossi’, Piazzale L.A. Scuro, 37134 Verona, Italy (e-mail:
zampius@libero.it).
 
Accepted 24 February 2006
 
DOI: 10.1111/j.1365-2354.2006.00683.x
 
INTRODUCTION
 
Rhabdomyosarcoma (RMS), a soft tissue malignant mus-
culoskeletal tumour, accounts for approximately 1% of
the cases of cancer among children aged 0–14 years and
2% of the cases among adolescents and young adults aged
between 15 and 18 years (Iwai 
 
et al
 
. 1990).
In most children, it develops as a localized disease cur-
able with combined modality therapy, with a survival rate
of 
 
>
 
75% after 5 years from diagnosis.
Rhabdomyosarcoma is the most common tumour of the
biliary tree in childhood, accounting for 1% of all paedi-
atric RMS (Martinez 
 
et al
 
. 1982).
Rhabdomyosarcoma occurs infrequently in the liver and
biliary tree with only 45 cases reported since 1975. The
management and prognosis of this tumour is constantly
changing as new imaging techniques and chemotherapy as
initial treatment become available (Maurer 
 
et al
 
. 1988;
Crist 
 
et al
 
. 2001).
 
CASE REPORT
 
In March 2002, O.A.M., a 3-year-old Nigerian girl, was
hospitalized for jaundice, aenemia and hepatomegaly,
with WBC 17 000, AST 170, ALT 139 and total Bilirubin
16.54 mg/mL.
Objective examination showed a distended abdomen,
with no pain during both superficial and deep palpation.
There was no report of either hereditary diseases or pre-
vious episodes of abdominal pain.
An abdominal US scan showed an expansive formation
with a diameter of about 6 cm and a mixed (solid and liq-
uid) echostructure at the site of the hepatic hilum.
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It also showed significant cystic duct ectasia, with small
gallstones in the duct lumen.
Nuclear magnetic resonance showed a dilation of the
common hepatic duct as well as a significant dilation of
the choledochus duct up to its extra-pancreatic tract
(Fig. 1).
The patient was then transferred to our Department
with a diagnosis of choledochal cyst to undergo corrective
surgery.
During super-umbilical transverse laparotomy, we found
a major choledochal cystic formation which was difficult
to isolate and remove (Fig. 2). The gallbladder appeared dis-
tended with tense neoformation surrounded by inflamma-
tory tissue. Complete avulsion of the extra-hepatic duct
and a Roux-en-Y hepatico-jejunostomy, without antireflux
jejunum valve, was therefore performed (Fig. 3).
Histology revealed a botryoid RMS of the extra-hepatic
bile duct (with a diameter of 5 cm) affecting both the cho-
ledochus and the common hepatic duct. There was also
evidence of translucent polypoid formations both in the
choledochus and in the common hepatic duct. The neo-
plasia developed near the margin of the proximal resection
(hepatic duct), with a report of chronic cholecystitis.
Pericystic lymph nodes did not show significant struc-
tural changes.
Ten days after surgery, the patient was then transferred
to the Paediatric Oncohaematology Unit and therefore
discharged after 20 days.
The patient was included in to the IIa group of the Inter-
group Rhabdomyosarcoma Clinical Groups Classification
(Table 1). She received three chemotherapy cycles with
 
Figure 1.
 
Abdominal MRI at the level of the hepatic hilum. MRI,
magnetic resonance imaging.
 
Figure 2.
 
Choledochal mass.
 
Figure 3.
 
Excision of the mass and hepaticojejunostomy and
Roux-en-Y anastomosis.
 
Table 1.
 
Intergroup Rhabdomyosarcoma Clinical Groups
Group Residual tumor after resection
I None (gross or microscopic)
IIa Microscopic residual tumour at primary site; 
pathologic negative nodes
IIb No residual tumour at primary site; pathologic 
positive nodes
IIc Microscopic residual tumour at primary site and
pathologic positive nodes
III Gross residual tumour
IV Distant metastasis
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Vincristine, Actinomycin D, Ifosfamide and Adriamicyn
(V.A.I.A), in accordance with Intergroup Rhabdomyosar-
coma Study Group IV. A CT scan carried out 8 and
18 months after surgery confirmed that distance metasta-
sis did not develop. At present, the patient is being fol-
lowed by our staff and is disease free.
 
DISCUSSION
 
Botryoid RMS of the biliary tree is a very rare tumour and
the first case was described by Wilks and Moxon in 1875
(Wilks & Moxon 1875; Aggarwal 
 
et al
 
. 2004).
It accounts for 1% of all RMSs, occurring predomi-
nantly in infants with a clear preponderance of male
patients. About 2% of tumours are present at birth. Inter-
mittent jaundice with or without abdominal distension,
fever and anorexia is the typical presentation.
In the past few years, the approach to sarcoma botry-
oides of the biliary tree has apparently changed. Recently,
all  patients  classified  as  stage  I,  including  those  treated
at our Department, have undergone aggressive surgical
resection and subsequent adjuvant therapy. After diagno-
sis, their mean survival rate is 5 years (80%) (Neville 
 
et al
 
.
2000).
The Intergroup Rhabdomyosarcoma Study Group
(IRSG), the National Wilms’ Tumor Study Group and
other two large cooperative paediatric cancer treatment
groups have recently merged to form the Children’s
Oncology Group (COG). Within COG, the Soft Tissue Sar-
coma Committee (STS-COG) has developed new proto-
cols for children with soft tissue sarcoma. In addition to
IRSG, current STS-COG protocols also use a Tumour–
Node–Metastasis (TNM)-based pre-treatment staging sys-
tem. The disease stage is clinically determined by primary
tumour site and size, regional lymph node status, with or
without metastases (Table 2) (Lawrence 
 
et al
 
. 1987, 1997).
The STS-COG includes patients into different treat-
ment protocols using a risk classification scheme combin-
ing the information about clinical group and disease stage
described in this report. For protocol purposes, patients
are classified as low, intermediate, or high risk (Table 3)
(Breneman 
 
et al
 
. 2001; Raney 
 
et al
 
. 2001).
The extent of surgical resection currently recom-
mended depends on primary tumour site, and initial com-
plete resection is generally recommended if it does not
involve loss of organ function. Undetectable distant
metastases at diagnosis, grossly complete surgical
removal of localized tumour, botryoid histology, tumour
size 
 
<
 
 5 cm and patient’s age 
 
<
 
 10 years at the time of diag-
nosis are favourable prognostic factors. We also want to
stress the importance of assessing regional lymph nodes
since histological evaluations showed that more than 75%
of patients with clinically negative regional nodes also
developed microscopic tumour. This finding is important
for staging and grouping purposes, affecting also chemo-
therapy regimen, follow-up and prognosis (Lack 
 
et al
 
.
1981; Geoffray 
 
et al
 
. 1987; Derek 
 
et al
 
. 1998; Spunt 
 
et al
 
.
2000).
Some authors recommend surgical exploration at the
time of diagnosis only to confirm the diagnosis and to
determine the extent of the regional disease. To this pur-
pose, they suggest to perform a suitable incisional biopsy
of the tumour and to explore the abdomen thoroughly to
search for evidence of metastatic disease.
These authors also recommend minimally invasive bil-
iary tract drainage procedures at diagnosis, like the place-
 
Table 2.
 
Stage classification
 
•
 
Stage 1
 
: Localized disease involving the orbit or head and neck (excluding parameningeal sites), or genitourinary region (excluding 
bladder/prostate sites), or biliary tract (favourable sites).
 
•
 
Stage 2
 
: Localized disease of any other primary site not included in the stage 1 category (unfavourable sites). 
Primary tumours must be 
 
≤
 
5 cm in diameter, and there must be no clinical regional lymph node involvement by tumour.
 
•
 
Stage 3
 
: Localized disease of any other primary site. These patients differ from stage 2 patients by having primary 
tumours greater than 5 cm and/or regional node involvement.
 
•
 
Stage 4
 
: Metastatic disease at diagnosis.
The disease stage is clinically determined by primary tumour site and size, regional lymph node status, with or without metastases.
 
Table 3.
 
Risk classification scheme
 
•
 
Low risk
 
: patients with localized embryonal rhabdomyosarcoma occurring at favourable sites (i.e. stage 1) (Groups I, II and III) and 
patients with embryonal rhabdomyosarcoma occurring at unfavourable sites with either completely resected disease (i.e. Group I) or 
microscopic residual disease (i.e. Group II).
 
•
 
Intermediate risk
 
: patients with embryonal rhabdomyosarcoma occurring at unfavourable sites with gross residual disease (i.e. Group 
III), patients with metastatic embryonal rhabdomyosarcoma who are younger than 10 years, and patients with non-metastatic alveolar 
rhabdomyosarcoma or undifferentiated sarcoma at any site.
 
•
 
High risk
 
: patients with metastatic rhabdomyosarcoma or undifferentiated sarcoma at presentation excepting embryonal cases in 
children younger than 10 years.
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ment of an endoscopic stent. If stent placement is not
possible, chemotherapy should be immediately started to
try and decompress the biliary tract (Sanz 
 
et al
 
. 1997; Pol-
lono 
 
et al
 
. 1998; Spunt 
 
et al
 
. 2000).
We do agree with these authors, but we also believe that
when treating children with the most favourable progno-
sis, like those under treatment at our Department, it is
important to ensure high survival rates (
 
>
 
90%) and mini-
mize long-term consequences of chemotherapy (Maurer
 
et al
 
. 1988, 1993; Crist 
 
et al
 
. 1995).
 
CONCLUSION
 
In the last 20 years, the rate of disease-free survival for
patients affected by RMS of the hepatic bile tree has sig-
nificantly increased.
Oncologic surgery certainly plays a key role in the sur-
vival of these patients and disease staging. The introduc-
tion of chemotherapy and radiotherapy has certainly
improved the treatment timing of RMS. At Stage 1, aggres-
sive surgical therapies together with chemotherapy have
increased the survival rate of patients after 5 years up to
80%.
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